Why Russian nootropics never crossed the Atlantic — Semax, Selank, Cortexin, and the regulatory gap

This is the strange fact at the center of Russian nootropic pharmacology: a body of clinical medicine, developed over decades with real patients and published data, that simply does not exist from the perspective of Western medical practice.

It isn't unique to Semax. Selank has been approved in Russia since 2009 for anxiety disorders and asthenic conditions. Cortexin has been in clinical use since the 1980s. Cerebrolysin, a preparation of neurotrophic peptides from pig brain, is used across Eastern Europe and parts of Asia for stroke rehabilitation. Each of these compounds has a clinical footprint in its home jurisdiction — prescribed by licensed physicians, manufactured under pharmaceutical-grade standards, with approved indications and dosing protocols — and virtually none of that footprint is visible to Western medicine. The clinical experience might as well not exist.

Understanding why requires tracing the exact mechanisms by which a compound moves from research to clinical legitimacy in the Western system, and why these particular compounds couldn't travel that path.

The randomized controlled trial is the currency of Western clinical evidence. Not the controlled trial or the observational study or the case series — the double-blind, placebo-controlled, pre-registered, adequately powered RCT conducted under Good Clinical Practice standards. This model was consolidated after the thalidomide crisis of the late 1950s and early 1960s, and by the 1980s it had become the required evidentiary standard for drug approval in the United States and Europe. The FDA does not approve drugs on the basis of observational data, case series, or clinical experience alone, no matter how extensive. The EMA operates similarly. The RCT is not a preference — it is a regulatory requirement.

The Soviet and Russian clinical trial tradition developed along different lines. It was not built around the RCT in the Western sense. Russian clinical research — even well-funded, institutionally serious research — tended to favor controlled clinical trials that were neither fully randomized nor always blinded, with smaller sample sizes, flexible outcome measures, and statistical approaches that don't map onto the FDA's requirements. This isn't because Russian researchers were unscientific. It's because they were operating within a system that defined clinical evidence differently, one shaped by different regulatory pressures, different scientific culture, and different resource constraints. The studies were real. The conclusions often held up in practice. But the methodology, by FDA standards, was insufficient.

So the first problem is methodological: even the best Russian clinical trials for Semax or Cortexin would face significant hurdles in an FDA submission, not because the science is bad but because the trial design doesn't satisfy Western regulatory requirements.

The second problem is linguistic and infrastructural. For most of the Soviet period and into the 1990s, this research was published exclusively in Russian-language journals — often in publications that were not indexed in international databases, that were not translated into English, and that Western scientists never encountered. The PubMed record for these compounds is thin to this day; the actual research base lives in Russian-language archives that most Western researchers have never accessed and couldn't read without translation assistance. A Western scientist doing a literature review would conclude there was little to no evidence for Semax — not because little evidence exists, but because the evidence exists in a language and in journals outside the horizon of Western science infrastructure. The gap was not discovered information; it was information that the architecture of knowledge dissemination had rendered effectively invisible.

The third problem is commercial, and it may be the most decisive. Western pharmaceutical development is funded by commercial interest. The typical path for a compound from discovery to FDA approval costs somewhere between five hundred million and two billion dollars in clinical development alone. No institution undertakes that investment without a credible path to commercial return — which means patent protection, market exclusivity, and a sufficiently large patient population. Short peptides are difficult to patent in commercially durable ways. They're small, structurally simple, and in many cases structurally close to naturally occurring sequences. Semax is a modified fragment of a hormone the body produces; Selank is a modified fragment of tuftsin, which is derived from immunoglobulin G. The patent landscape for these compounds doesn't offer the kind of exclusivity that would make a multi-billion-dollar Western development program economically rational. No large pharmaceutical company was going to fund FDA trials for a compound they couldn't hold an exclusive position on.

Without commercial sponsorship, there is no FDA process. Without FDA process, there is no approval. Without approval, there is no integration into clinical guidelines. Without clinical guidelines, the compounds simply don't exist for practicing physicians in the United States or Western Europe — regardless of what the actual evidence says.

The result is two parallel universes of clinical experience that evolved independently for decades. In Russia and CIS countries: routine prescribing, accumulated clinical observation, real-world safety data, continued development of second- and third-generation analogs. In Western countries: complete absence from the medical record, zero clinical familiarity, and — eventually — a growing consumer market operating outside the medical system entirely, as individuals who discovered these compounds through longevity forums and research communities began importing or sourcing them through compounding pharmacies.

That consumer interest is, paradoxically, part of what's beginning to close the gap. The past decade has brought a meaningful increase in English-language attention to the Russian nootropic literature. Researchers in Western longevity and cognitive science communities have started citing the Russian work, translating it, and in some cases replicating it in Western preclinical models. Semax has attracted preclinical work in American and European laboratories. Selank has been studied in rodent models at institutions outside Russia. Some of the Cortexin literature has been translated and meta-analyzed in English. The gaps are not closing quickly, and they are not closing through the formal clinical development process — but the information is at least beginning to reach the researchers who might evaluate it.

What the compounds deserve — and largely haven't received — is a serious, adequately powered, methodologically rigorous Western trial. Not because the Russian literature is worthless, but because the Western clinical standard exists for good reasons, and applying it to these compounds would either validate what decades of Russian clinical use suggest or identify the places where the evidence doesn't hold up. Either outcome would be useful.

The regulatory gap also teaches something about the path that determines what becomes medicine and what doesn't. The path is not purely scientific. It runs through commercial interest, through patent law, through the economics of clinical development, through language barriers and publication infrastructure, through the specific methodology a regulatory agency has decided to require. Compounds can have real biological effects, real clinical utility, and decades of real-world use, and still not exist in Western medical practice because none of the mechanisms that move something from research to prescription aligned with their particular situation.

Semax, Selank, Cortexin, and the rest of the Russian nootropic catalog didn't fail to cross the Atlantic because the evidence was absent. They didn't cross because the infrastructure for crossing required commercial investment that wasn't available, regulatory standards that weren't met by the existing studies, and a publication ecosystem that kept the research invisible until the internet began dissolving those walls. What's on the other side of the gap is not nothing. It may take another decade, or two, to know with the precision Western medicine demands exactly how much of it is real.